Form 4: Pfizer CEO Bourla Acquires Phantom Stock Units

Pfizer CEO Albert Bourla acquired 25 phantom stock units as part of a deferred compensation plan, increasing his beneficial ownership to 730,907 units.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc. (PFE), acquired 25 phantom stock units.
• The transaction occurred on September 15, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• The units were acquired at a price of $23.97 per unit.
• Following this transaction, Bourla beneficially owns 730,907 phantom stock units.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• The units are settled in cash upon Bourla's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 6

Explanation: The acquisition of phantom stock units by the CEO is a moderately positive signal, indicating continued alignment with the company's performance, although the units are cash-settled and the transaction size is small relative to total holdings.

Positives

• The acquisition of phantom stock units by the CEO demonstrates continued alignment of management's interests with shareholder value, even if cash-settled.
• The transaction is part of a structured compensation plan, indicating stability in executive remuneration.

Negatives

• The acquired units are phantom stock, meaning they are cash-settled and do not represent direct equity ownership or voting rights.
• The number of units acquired (25) is a relatively small amount compared to the CEO's total beneficial ownership and the company's market capitalization, limiting its significance as a strong bullish signal.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure related to executive compensation and does not provide specific insights into broader pharmaceutical industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction reinforces management's vested interest in the company's long-term performance through a compensation plan, potentially fostering confidence.
• Employees: The deferred compensation plan highlights a structured approach to executive incentives, which may influence broader compensation strategies.

Key Dates

Recommendation

This Form 4 filing details a routine, compensation-related acquisition of a small number of phantom stock units by the CEO. It does not provide new material information about Pfizer's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is expected and does not significantly alter the investment thesis for a large-cap pharmaceutical company like Pfizer.

Keywords

Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Deferred Compensation, Executive Compensation